27 / 48
27
WFSBP 2017
Symposia
/ Preliminary Scientific Programme
S-38-002
A longitudinal perspective on the evolution of treatment
resistance
Ofer Agid, Canada
S-38-003
The biology of treatment resistance
Oliver Howes, United Kingdom
S-38-004
Definitions and epidemiology of treatment resistance
Christoph U. Correll, USA
T1: ADDICTIVE DISORDERS
S-39
15:00–16:30
Current research on the use of cannabinoids
Chair:
Aviv Weinstein, Israel
Co-Chair: Amine Benyamina, France
S-39-001
Cannabis use disorder and its effects on cognitive function
Valerie Curran, United Kingdom
S-39-002
The relationship between cannabis and psychosis
Deepak Cyril D´Souza, USA
S-39-003
The genetics of cannabis use disorder
Amine Benyamina, France
S-39-004
The effects of chronic use of synthetic cannabinoids on
executive brain function
Aviv Weinstein, Israel
T10: DEMENTIA: BASIC/CLINICAL
S-40
15:00–16:30
Alzheimer's Disease (AD) pathophysiology, prevention
and treatment strategies: Where we stand and where
we go?
Chair:
Jerzy Leszek, Poland
Co-Chair: Ramon Cacabelos, Spain
S-40-001
Pharmacogenetics of cerebrovascular phenotypes of risk
in dementia
Ramon Cacabelos, Spain
S-40-002
Insulin resistance in neurodegeneration: The role of
p53/miRNA/SIRT1 axis
Kazimierz Gasiorowski, Poland
S-40-003
Alzheimer drug discovery: Targeting synaptic glutamate
signaling
Markku Kurkinen, USA
S-40-004
Nanotechnology for early detection and treatment of
Alzheimer's Disease (AD): Where we stand and where
we go?
Jerzy Leszek, Poland
T47: STIMULATION METHODS (ECT, TMS, VNS, DBS)
S-41
15:00–16:30
Electroconvulsive therapy for depression – optimising
treatment and maintaining recovery
Chair:
Declan McLoughlin, Ireland
Co-Chair: Pascal Sienaert, Belgium
S-41-001
The KEEP-WELL Trial: Ketamine for depression relapse
prevention following ECT (NCT02414932)
Declan McLoughlin, Ireland
S-41-002
Immediate and long-term outcomes for Brief-pulse (BP)
vs Ultrabrief-pulse (UBP) high-dose unilateral ECT: The
ResPECT trials’ experience
Pascal Sienaert, Belgium
H.-P. Spaans, E. Verwijk, F. Bouckaert
S-41-003
Pre- and post-ECT cognitive performance as predictors
for outcome and relapse in depression (NTR1304)
Esmée Verwijk, The Netherlands
S-41-004
The PRIDE Trial – Prolonging remission in depressed
elderly (NCT01028508): Results from the randomised
phase
Charles Kellner, USA
T22: MOLECULAR NEUROBIOLOGY
S-42
17:00–18:30
Neuroepigenetic approaches to assess disease risk,
mechanism and treatment
Chair:
Alfonso Buil, Denmark
Co-Chair: Jonathan Mill, United Kingdom
S-42-001
CACNA1C hypermethylation associated with Bipolar
Disorder (BD)
Anna Starnawska, Denmark
D. Demontis, A. Pen, A. Hedemand, A. L. Nielsen,
TUE